MONMOUTH JUNCTION, N.J.,
Jan. 21, 2016 /PRNewswire/
-- CytoSorbents Corporation (NASDAQ: CTSO), a critical care
immunotherapy leader commercializing its European Union approved
CytoSorb® blood filter to treat deadly inflammation in
critically-ill and cardiac surgery patients worldwide, today
announced that Dr. Volker Humbert,
M.D. has joined the company as Senior Manager of Clinical
Affairs.
Dr. Humbert, anesthesiologist and intensivist, joined
CytoSorbents from PULSION Medical Systems, a leader in critical
care hemodynamic monitoring which was acquired by Maquet Medical
Systems AG, a subsidiary of Getinge Group, in 2014. "It is great to
join CytoSorbents' very dynamic and competent team," said Dr.
Humbert. "With my clinical knowledge and experience from my
years as a Medical Director for Pulsion, I look forward to
strengthening the medical expertise of the company and providing
comprehensive medical support and education to medical
professionals worldwide using CytoSorb® to help patients. I
truly believe that CytoSorb® has huge potential and can
change critical care medicine fundamentally."
Dr. Humbert has as an extensive leadership career in critical
care and emergency medicine, treating critically-ill patients in
the intensive care unit, providing surgical anesthesia during
cardiac surgery, and managing patients post-operatively. His
diverse set of skills and expertise also includes regulatory
affairs, medical advisory board management, product safety
monitoring, sales, marketing training and support, medical
consulting, and project management. Dr. Humbert received his
academic and doctoral degrees from Ludwigs-Maximilians University
of Munich, received specialist training in both critical care and
emergency medicine at Hospital Munich-Bogenhausen, is certified as
a specialist in intensive care medicine and anesthesia by the
Bavarian Medical Association in Munich,
Germany, served as an emergency physician for the Austrian
Red Cross, and completed coursework for medical engineering at the
University of Keiserslautern.
"We are very fortunate to add Dr. Humbert as a member of the
CytoSorbents team," said Dr. Phillip
Chan, CEO of CytoSorbents. "As we continue to expand
the global footprint of CytoSorb® in both critical care medicine
and cardiac surgery, his wealth of clinical and industry expertise
is a perfect fit to help strengthen communication, awareness, and
education amongst physicians and healthcare professionals across
all of our sales territories. We are confident that Dr. Humbert
will have an immediate and long-term impact in accelerating usage,
adoption, and sales of CytoSorb®."
About CytoSorbents Corporation
CytoSorb® is approved in the European Union with distribution in
32 countries around the world, as a safe and effective
extracorporeal cytokine adsorber, designed to reduce the "cytokine
storm" that could otherwise cause massive inflammation, organ
failure and death in common critical illnesses such as sepsis, burn
injury, trauma, lung injury, and pancreatitis. These are
conditions where the risk of death is extremely high, yet no
effective treatments exist. CytoSorb® is also
being used during and after cardiac surgery to remove inflammatory
mediators, such as cytokines and free hemoglobin, which can lead to
post-operative complications, including multiple organ
failure. CytoSorb® has been used safely in more than 9,000
human treatments to date.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. The Company has numerous products
under development based upon this unique blood purification
technology, protected by 32 issued U.S. patents and multiple
applications pending, including HemoDefend™, ContrastSorb,
DrugSorb, and others. Additional information is available for
download on the Company's websites:
http://www.cytosorbents.com and http://www.cytosorb.com
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 31, 2015, as updated by the risks reported in
our Quarterly Reports on Form 10-Q, and in the press releases and
other communications to shareholders issued by us from time to time
which attempt to advise interested parties of the risks and factors
which may affect our business. We caution you not to place undue
reliance upon any such forward-looking statements. We undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, other than as required under the Federal securities
laws.
Please Click to Follow Us on Facebook and Twitter
Cytosorbents Contact:
Amy
Vogel
Investor Relations
(732) 329-8885 ext. *825
avogel@cytosorbents.com
Investor Contact:
Lee
Roth
The Ruth Group
646-536-7012
lroth@theruthgroup.com
Public Relations Contact:
Eric
Kim
The Ruth Group
646-536-7023
ekim@theruthgroup.com
Logo- http://photos.prnewswire.com/prnh/20140408/MM00899LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cytosorbents-appoints-dr-volker-humbert-as-senior-manager-of-clinical-affairs-300207764.html
SOURCE CytoSorbents Corporation